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In 2011, member states of the UN General Assembly 
established an objective to reduce premature deaths 
from non-communicable diseases (including cancer) 
by 25% by 2025.1 A reduction in cancer mortality can 
only be achieved through disease control programmes 
that include prevention, early diagnosis, and treatment 
of malignant disease. N early a decade ago, the World 
Health Assembly called on its member states to create 
“national cancer plans and programs”.2 The need 
for such initiatives has escalated in the intervening 
years. The burden of cancer is growing worldwide, 
not only because the population is ageing in many 
countries (attributable in part to improved control of 
communicable diseases) but also because of changes 
in risk factors (eg, increasing prevalence of tobacco 
smoking and obesity).3 To establish priorities for 
cancer control programmes, governments must have 
suﬃ  cient information to record the burden of cancer 
in their countries. Comprehensive, high-quality cancer 
registration is a key component needed to assess the 
eﬀ ectiveness of disease control programmes, and cancer 
registries have been endorsed by WHO.4
In The Lancet, Claudia Allemani and colleagues in the 
CONCORD Working Group5 describe the eﬀ orts of the 
CONCORD-2 programme to initiate global surveillance 
of cancer survival, examining survival trends from 
1995 to 2009. They assembled a global cancer dataset, 
with information for almost 26 million individual 
cancer patients provided by 279 population-based 
cancer registries in 67 countries.5 The group must be 
commended for the technical, scientiﬁ c, and political 
eﬀ orts needed to obtain these data.
Allemani and colleagues5 report an increase in 5-year 
survival from colon, rectal, and breast cancer in most 
developed countries. One striking ﬁ nding was for 
childhood acute lymphoblastic leukaemia, for which 
very wide variations in survival were noted globally—eg, 
less than 60% in several countries but 90% or higher in 
Canada and four European countries (Austria, Belgium, 
Germany, and Norway)—which suggests an absence of 
adequate treatment for children in particular regions 
of the world. The potential for cancer prevention 
programmes was highlighted by poor survival in most 
countries from lung and liver cancer—generally 10–20% 
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(for both cancers, 5-year survival is below 20% in 
Europe, 15–19% in North America, and as low as 7–9% 
in Mongolia and Thailand). Most countries have not 
seen signiﬁ cant improvement in 5-year survival from 
ovarian cancer, which generally varies between 30% 
and 50%; only ten of 61 countries have seen increases 
in survival of more than 5% between 1995–99 and 
2005–09, and for women diagnosed during 2005–09, 
5-year survival exceeded 40% only in Ecuador, the USA, 
and 17 countries in Asia and Europe. The improvement 
up to 2005–09 in 5-year survival from cervical cancer, a 
cancer that can be screen detected, has generally been 
limited, ranging from below 50% to 70% or higher. 
This contrasts with survival trends for prostate cancer. 
Allemani and colleagues report increases of 10–20% 
in 5-year prostate cancer survival between 1995–99 
and 2005–09 in 22 countries in South America, Asia, 
and Europe, but the global range is still wide, from less 
than 60% in Bulgaria and Thailand to 95% or more in 
Brazil, Puerto Rico, and the USA. These increases are 
probably due in large part to the increasingly widespread 
use of PSA testing for earlier detection. Early diagnosis 
and treatment of malignant disease are likely to have 
played a part in the global variability in cancer survival. 
Survival patterns and trends provide researchers and 
policy makers with evidence of the eﬀ ectiveness of 
cancer control programmes, and the ﬁ ndings of this 
global analysis can be used to plan and evaluate such 
programmes.
Although the CONCORD-2 analysis provides valuable 
information about cancer survival trends by country, 
Allemani and colleagues5 also highlight the scarcity 
of data available to assess the burden of cancer 
worldwide. Many areas of the world do not have high-
quality population-based cancer registration or did 
not participate in this global eﬀ ort. Scant coverage 
of particular geographical regions might represent 
areas where patients are at greater risk of either being 
diagnosed with cancer, being diagnosed at a late stage, 
or receiving low-quality care. Regions within a country 
that are not covered by a cancer registry might be areas 
of lower income, have poorer health care, or be sparsely 
populated.
Countries that operate population-based cancer 
registries face increasing challenges. Creating and 
maintaining nationally representative population-
based cancer registration is complex and needs 
resources and political commitment. High-quality 
cancer registries will have at least 90% ascertainment 
of cases, with fewer than 5% of cases registered from 
a death certiﬁ cate only, and will obtain high-quality 
data related to the site, stage, and morphological 
features of cancers.6 The potential value of a cancer 
registry is diminished if the population is not 
covered completely or if cases are under-ascertained. 
Moreover, many registries have only scant information 
about patients’ outcomes and do not have the 
capacity to link cancer registrations to other data. 
Comprehensive ascertainment of the date and cause 
of death in registered cancer patients would enhance 
the usefulness of registries to assess the burden of 
malignant disease.
Implementation of eﬀ ective cancer control 
programmes, including the operation of population-
based cancer registries, needs support from national 
governments. For low-income and middle-income 
countries, such eﬀ orts might be diﬃ  cult, taking into 
account economic capabilities. Patients, patient 
advocates, health-care providers and administrators, 
researchers, and the wider community can all play 
a part in inﬂ uencing politicians to provide funds for 
cancer control eﬀ orts. Evaluation of cancer control 
programmes will serve as a reinforcing mechanism to 
maintain funding and lead to improvements in these 
initiatives.
In view of the value of data resources such as cancer 
registries, we would not expect their existence to be 
at risk. However, as Allemani and colleagues5 note, 
concerns are mounting about pending legal and 
regulatory issues and privacy concerns that could 
restrict the registration of cancer patients and access 
to data for research.7,8 This proposed legislation seems 
counterproductive to the goal all countries must 
have to diminish suﬀ ering and death from cancer. 
Data for research are anonymised, without personal 
identiﬁ ers, and are reported in broad categories to 
enable protection of patients’ identities and provide 
conﬁ dentiality. What would be gained by restricting 
researchers’ access to these data is not clear; the loss to 
society is much clearer.
The analyses of global survival reported by Allemani 
and colleagues provide an opportunity for lessons 
to be learnt from countries with successful cancer 
control initiatives, which could be applied to other 
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The Independent Panel on Global Governance for Health 
(the Panel), established for an initial period of 3 years, 
is a collaborative initiative between the University 
of Oslo, Oslo, Norway and The Lancet, following the 
recommendations of The Lancet-University of Oslo 
Commission on Global Governance for Health, published 
on Feb 11, 2014.1 
The objective of the Panel is to provide evidence, 
based on high quality, independent research and 
analysis, which can be used to inform and guide political 
processes that aﬀ ect global health. The legitimacy and 
authority of the Panel are based on the independence 
and academic quality of its work. 
The Panel is supported by an Advisory Board, 
chaired by the former Chair of the Commission, 
Ole Petter Ottersen (President of the University of Oslo). 
Members of the Advisory Board and the Panel have 
been nominated by him, subject to approval by former 
members of the Commission. The topic to be addressed 
by the Panel each year is decided in agreement with the 
Advisory Board. 
The Panel is preparing a report to be published in 
The Lancet in 2015. The topic is “the implications for 
health and the social determinants of health of trade 
and investment treaties, agreements, and negotiation 
processes”.
International trade and investment agreements 
can have major eﬀ ects—both positive and negative—
on people’s health and wellbeing. The eﬀ ects can be 
broad, for example on agriculture, the availability and 
safety of food, and employment. Agreements can also 
aﬀ ect health directly, for example through rules that 
aﬀ ect access to and availability of drugs, labelling of 
food, or environmental regulation. A crucial issue is the 
eﬀ ect of trade and investment agreements on policy 
space—ie, the freedom, scope, and mechanisms that 
governments have to choose, design, and implement 
public policies to fulﬁ l their aims. These agreements 
are formalised and interpreted according to complex 
and technical legal procedures. Powerful states and 
corporations exert a strong pressure on the outcome 
because of the substantial resources they bring to the 
negotiating table. As a result, aﬀ ected communities and 
stakeholders might be excluded from the process.
Panel members share responsibility for writing the 
report, but will also draw on contributions from other 
researchers and experts. The Panel hereby invites 
submissions of evidence on this topic from all interested 
parties, including those in academia, civil society, 
business, administration, and the public. 
We are particularly interested to receive submissions 
on the following three themes. First, the eﬀ ects of 
trade and investment agreements, and negotiation 
processes, on: environmental and workplace 
health, safety, and labelling standards; increasing 
trade in unhealthy commodities (eg, tobacco and 
Trade and investment agreements: a call for evidence 
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regions. Undoubtedly, the availability of better data 
provides a clearer picture of the eﬀ ect of cancer control 
programmes on the ultimate goal of improving survival 
and reducing the eﬀ ect of cancer on the social and 
economic development of countries.
*Linda C Harlan, Joan L Warren
National Cancer Institute, Bethesda, MD 20892, USA
harlanl@mail.nih.gov
We declare no competing interests. This Comment is solely the responsibility of 
the authors and does not necessarily represent the oﬃ  cial views of the National 
Cancer Institute or the National Institutes of Health.
Copyright © Harlan et al. Open Access article distributed under the terms of 
CC BY.
1 Kontis V, Mathers CD, Rehm J, et al. Contribution of six risk factors to 
achieving the 25 × 25 non-communicable disease mortality reduction 
target: a modelling study. Lancet 2014; 384: 427–37.
2 Nieburg HE. Cancer prevention and control strategy resolution adopted by 
the 58th World Health Assembly, Geneva, May 25, 2005. 
Cancer Detect Prev 2005; 29: 403–04.
3 Vineis P, Wild CP. Global cancer patterns: causes and prevention. 
Lancet 2014; 383: 549–57.
4 Valsecchi MG, Steliarova-Foucher E. Cancer registration in developing 
countries: luxury or necessity? Lancet Oncol 2008; 9: 159–67.
5 Allemani C, Weir HK, Carreira H, et al, and the CONCORD Working Group. 
Global surveillance of cancer survival 1995–2009: analysis of individual 
data for 25 676 887 patients from 279 population-based registries in 
67 countries (CONCORD-2). Lancet 2014; published online Nov 26. 
http://dx.doi.org/S0140-6736(14)62038-9.
6 Bray F, Parkin DM. Evaluation of data quality in the cancer registry: 
principles and methods—part I, comparability, validity and timeliness. 
Eur J Cancer 2009; 45: 747–55.
7 Casali PG. Risks of the new EU data protection regulation: an ESMO 
position paper endorsed by the European oncology community. Ann Oncol 
2014; 25: 1458–61.
8 Thomas B, Gostin LO. Tackling the global NCD crisis: innovations in law and 
governance. J Law Med Ethics 2013; 41: 16–27.
